BACKGROUND Malaria control programmes need to protect young children, who bear the brunt of malaria disease and death in Africa.
The development of a vaccine is a priority if improved and sustained malaria control is to be achieved.
The best use of a vaccine in Africa will be achieved if it can be delivered through the expanded programme of immunization (EPI).
We conducted a trial designed to evaluate the efficacy of SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania.
METHODS The study was a two-arm, double blind, individually randomized placebo controlled trial involving 1207 infants.
The primary objective of the trial was to estimate the efficacy of three doses of SPf66 given at 1,2 and 7 months of age in preventing clinical episodes of malaria.
These were documented through a health facility-based passive case detection system.
RESULTS Among 1207 randomized children, overall compliance for third dose was 91%. SPf66 was safe, immunogenic and did not interfere with the humoral immune responses to EPI vaccines.
There were 294 children among SPf66 recipients and 288 among placebo recipients with at least one malaria episode, yielding a vaccine efficacy estimate of 2% (95% CI : - 16,16 ; P=0.84).
CONCLUSION This has been the first trial of a malaria vaccine among very young infants. (...)
Mots-clés Pascal : Paludisme, Protozoose, Parasitose, Infection, Plasmodium falciparum, Apicomplexa, Protozoa, Evaluation, Efficacité, Vaccin, Immunoprophylaxie, Posologie, Etude double insu, Randomisation, Nourrisson, Homme, Programme sanitaire, Tanzanie, Afrique
Mots-clés Pascal anglais : Malaria, Protozoal disease, Parasitosis, Infection, Plasmodium falciparum, Apicomplexa, Protozoa, Evaluation, Efficiency, Vaccine, Immunoprophylaxis, Posology, Double blind study, Randomization, Infant, Human, Sanitary program, Tanzania, Africa
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0343920
Code Inist : 002B05E02B4. Création : 14/12/1999.